Format

Send to

Choose Destination
See comment in PubMed Commons below
J Assist Reprod Genet. 2011 Sep;28(9):833-49. doi: 10.1007/s10815-011-9608-7. Epub 2011 Jul 9.

Preimplantation genetic screening: does it help or hinder IVF treatment and what is the role of the embryo?

Author information

1
Center for Reproductive Medicine, Cleveland Clinic, Cleveland, Ohio, USA. kimdaoly@yahoo.com

Abstract

Despite an ongoing debate over its efficacy, preimplantation genetic screening (PGS) is increasingly being used to detect numerical chromosomal abnormalities in embryos to improve implantation rates after IVF. The main indications for the use of PGS in IVF treatments include advanced maternal age, repeated implantation failure, and recurrent pregnancy loss. The success of PGS is highly dependent on technical competence, embryo culture quality, and the presence of mosaicism in preimplantation embryos. Today, cleavage stage biopsy is the most commonly used method for screening preimplantation embryos for aneuploidy. However, blastocyst biopsy is rapidly becoming the more preferred method due to a decreased likelihood of mosaicism and an increase in the amount of DNA available for testing. Instead of using 9 to 12 chromosome FISH, a 24 chromosome detection by aCGH or SNP microarray will be used. Thus, it is advised that before attempting to perform PGS and expecting any benefit, extended embryo culture towards day 5/6 should be established and proven and the clinical staff should demonstrate competence with routine competency assessments. A properly designed randomized control trial is needed to test the potential benefits of these new developments.

PMID:
21743973
PMCID:
PMC3169679
DOI:
10.1007/s10815-011-9608-7
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center